Compare Regeneron Pharmaceuticals Inc (REGN) vs Wix.Com Ltd (WIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Wix.Com Ltd — how do they compare? Regeneron Pharmaceuticals Inc trades at $739.58 (market cap $76.14B), while Wix.Com Ltd trades at $74.13 (market cap $3.11B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 24.5× Wix.Com Ltd's market cap, and Regeneron Pharmaceuticals Inc pays a 0.51% dividend while Wix.Com Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold Regeneron Pharmaceuticals Inc for 107 Days and Wix.Com Ltd for 62 Days on average.
| REGN | WIX | |
|---|---|---|
Market Cap | $76.14B | $3.11B |
Volume | 500,239 | 809,286 |
Sector | Health | Technology |
52-Week High | $852.03 | $145.54 |
52-Week Low | $557.73 | $40.43 |
Typical Hold Time | 107 Days | 62 Days |
Enterprise Value | $70.85B | $4.19B |
Dividend Yield | 0.51% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $742.12, up 0.46% on the day, with a bearish technical signal despite strong fundamentals. The stock shows robust profitability with a 27.86% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights a significant $8 billion immunology alliance expansion with Sanofi, providing substantial upfront and milestone payments.
The outlook is positive due to strong earnings momentum and strategic collaborations, but risks include competitive pressures in key drug markets and technical bearish indicators. Analyst consensus is bullish with a $849.84 price target, suggesting potential upside from current levels, though investors should monitor execution of new partnerships and pipeline developments.
Wix stock trades at $72.97, down 1.27% today, amid a bearish technical signal and mixed earnings. Recent quarters show volatility with a Q1 2026 miss but a Q2 beat. Revenue growth is solid, reaching $1.99B in 2025, but profitability remains weak with a negative net income margin. The stock faces headwinds from a securities class action lawsuit, with multiple law firms announcing deadlines in late September 2026.
The outlook is cautious; analyst consensus is bullish with a $77 price target, but high valuation ratios and legal risks offset growth potential. Investors should weigh strong revenue trends against profitability challenges and near-term sentiment pressure from litigation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Wix.Com Ltd
Wix.com Ltd is a cloud-based development platform provider for millions of registered users worldwide. The company is engaged in web development and management that provides an easy-to-use powerful cloud-based platform of products through a freemium model. Its core products consist of three web editors: the Wix Editor, intended for users with basic technological skills, Wix ADI, intended for novice users and Corvid, intended for more tech-savvy users. The company's web development technology is built based on HTML5 and offers HTML5 compatible capabilities, web design and layout tools, domain hosting, and other marketing and workflow management applications and services. The geographic segments include North America, Europe, Latin America, Asia and others.
Read more on WIX →
